Research programme: polyglutamine repeat disease therapies - Cogent Neuroscience/Elan
Alternative Names: Polyglutamine repeat disease therapies - Cogent Neuroscience/ElanLatest Information Update: 17 Jun 2003
At a glance
- Originator Cogent Neuroscience [CEASED]
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 06 Dec 2002 Discontinued - Preclinical for Huntington's disease in USA (unspecified route)
- 16 Mar 2001 Preclinical development for Huntington's disease in USA (Unknown route)